Thai H. Ho

47.3k total citations
122 papers, 3.6k citations indexed

About

Thai H. Ho is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Cancer Research. According to data from OpenAlex, Thai H. Ho has authored 122 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 81 papers in Pulmonary and Respiratory Medicine, 69 papers in Molecular Biology and 44 papers in Cancer Research. Recurrent topics in Thai H. Ho's work include Renal cell carcinoma treatment (66 papers), Renal and related cancers (38 papers) and Cancer Genomics and Diagnostics (31 papers). Thai H. Ho is often cited by papers focused on Renal cell carcinoma treatment (66 papers), Renal and related cancers (38 papers) and Cancer Genomics and Diagnostics (31 papers). Thai H. Ho collaborates with scholars based in United States, China and Canada. Thai H. Ho's co-authors include Thomas A. Cooper, Michael G. Poulos, Maurice S. Swanson, Richard W. Joseph, Nicolas Charlet‐Berguerand, Gopal K. Singh, Eric Jonasch, Dawna L. Armstrong, Donnie S. Bundman and John C. Cheville and has published in prestigious journals such as Cell, Proceedings of the National Academy of Sciences and Journal of Clinical Oncology.

In The Last Decade

Thai H. Ho

118 papers receiving 3.6k citations

Peers

Thai H. Ho

PRM

ONCOL

CMN

Leonard Girnita Sweden

Adrian M. Jubb United Kingdom

Elizabeth R. Lawlor United States

Paolo Michieli Italy

Susumu Saigusa Japan

Sergio Palomo‐Ponce Spain

Nina N. Nupponen Finland

Tokuzo Arao Japan

Samit Hirawat United States

Cristina Nadal Spain

Leonard Girnita Sweden

Thai H. Ho

2.5k ×1.1

352 ×0.2

PRM

898 ×1.0

781 ×1.0

ONCOL

182 ×0.4

CMN

Citations per year, relative to Thai H. Ho Thai H. Ho (= 1×) peers Leonard Girnita

Countries citing papers authored by Thai H. Ho

Since Specialization

Citations

This map shows the geographic impact of Thai H. Ho's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thai H. Ho with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thai H. Ho more than expected).

Fields of papers citing papers by Thai H. Ho

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thai H. Ho. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thai H. Ho. The network helps show where Thai H. Ho may publish in the future.

Co-authorship network of co-authors of Thai H. Ho

This figure shows the co-authorship network connecting the top 25 collaborators of Thai H. Ho. A scholar is included among the top collaborators of Thai H. Ho based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thai H. Ho. Thai H. Ho is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wagner, Ryan T., Ryan A. Hlady, Xiaoyu Pan, et al.. (2025). SETD2 loss-of-function uniquely sensitizes cells to epigenetic targeting of NSD1-directed H3K36 methylation. Genome biology. 26(1). 22–22. 2 indexed citations

Salem, S., Tiegang Han, Damir Khabibullin, et al.. (2025). Targeting FSP1 to induce ferroptosis in chromophobe renal cell carcinoma. Oncogene. 44(42). 4075–4086. 3 indexed citations

Wagner, Ryan T., Ryan A. Hlady, Xiaoyu Pan, et al.. (2023). SETD2 loss in renal epithelial cells drives epithelial‐to‐mesenchymal transition in a TGF‐β‐independent manner. Molecular Oncology. 18(1). 44–61. 3 indexed citations

Ho, Thai H., et al.. (2023). Generation and characterization of a monoclonal antibody that binds to Galectin-1. Protein Expression and Purification. 210. 106308–106308. 1 indexed citations

Adams, Daniel L., et al.. (2023). Cancer associated macrophage-like cells in metastatic renal cell carcinoma predicts for poor prognosis and tracks treatment response in real time. Scientific Reports. 13(1). 10544–10544. 4 indexed citations

Riaz, Irbaz Bin, Syed Arsalan Ahmed Naqvi, Huan He, et al.. (2022). Quantifying absolute benefit for adjuvant treatment options in renal cell carcinoma: A living interactive systematic review and network meta-analysis. Critical Reviews in Oncology/Hematology. 175. 103706–103706. 5 indexed citations

Eckel‐Passow, Jeanette E., Huihuang Yan, Matthew Kosel, et al.. (2020). 8q24 clear cell renal cell carcinoma germline variant is associated with VHL mutation status and clinical aggressiveness. BMC Urology. 20(1). 173–173. 1 indexed citations

Faigel, Douglas O., Eduard Sergienko, Andrey A. Bobkov, et al.. (2019). Molecular Inhibitor of QSOX1 Suppresses Tumor Growth In Vivo. Molecular Cancer Therapeutics. 19(1). 112–122. 19 indexed citations

Scheckel, Caleb, Heidi Kosiorek, Richard Butterfield, Thai H. Ho, & Talal Hilal. (2019). Germ Cell Tumors with Malignant Somatic Transformation: A Mayo Clinic Experience. Oncology Research and Treatment. 42(3). 95–100. 19 indexed citations

10.

Ho, Thai H., et al.. (2018). The Impact of Pazopanib on the Cardiovascular System. Journal of Cardiovascular Pharmacology and Therapeutics. 23(5). 387–398. 25 indexed citations

11.

Liu, Jingping, Erik P. Castle, Douglas F. Lake, et al.. (2018). Loss of SETD2 Induces a Metabolic Switch in Renal Cell Carcinoma Cell Lines toward Enhanced Oxidative Phosphorylation. Journal of Proteome Research. 18(1). 331–340. 37 indexed citations

12.

Ferdosi, Shadi, Thai H. Ho, Erik P. Castle, Melissa Stanton, & Chad R. Borges. (2018). Behavior of blood plasma glycan features in bladder cancer. PLoS ONE. 13(7). e0201208–e0201208. 16 indexed citations

13.

McDermott, David F., Richard W. Joseph, Thai H. Ho, et al.. (2017). A Phase (Ph) 1 dose finding study of X4P-001 (an oral CXCR4 inhibitor) and axitinib in patients with advanced renal cell carcinoma (RCC). Annals of Oncology. 28. v317–v318. 1 indexed citations

14.

Malouf, Gabriel G., Xiaoping Su, Jianping Zhang, et al.. (2016). DNA Methylation Signature Reveals Cell Ontogeny of Renal Cell Carcinomas. Clinical Cancer Research. 22(24). 6236–6246. 39 indexed citations

15.

Wong, William W., Homan Mohammadi, T.B. Daniels, et al.. (2016). Predictors for Survival After Radium-223 Treatment for Castration-Resistant Metastatic Prostate Cancer. International Journal of Radiation Oncology*Biology*Physics. 96(2). E255–E255. 1 indexed citations

16.

Ho, Thai H., Daniel Serie, Mansi Parasramka, et al.. (2016). Differential gene expression profiling of matched primary renal cell carcinoma and metastases reveals upregulation of extracellular matrix genes. Annals of Oncology. 28(3). 604–610. 67 indexed citations

17.

Joseph, Richard W., Sherri Z. Millis, Estrella M. Carballido, et al.. (2015). PD-1 and PD-L1 Expression in Renal Cell Carcinoma with Sarcomatoid Differentiation. Cancer Immunology Research. 3(12). 1303–1307. 131 indexed citations

18.

Choueiri, Toni K., David J. Figueroa, André P. Fay, et al.. (2014). Correlation of PD-L1 Tumor Expression and Treatment Outcomes in Patients with Renal Cell Carcinoma Receiving Sunitinib or Pazopanib: Results from COMPARZ, a Randomized Controlled Trial. Clinical Cancer Research. 21(5). 1071–1077. 187 indexed citations

19.

Choueiri, Toni K., André P. Fay, Kathryn P. Gray, et al.. (2014). PD-L1 expression in nonclear-cell renal cell carcinoma. Annals of Oncology. 25(11). 2178–2184. 242 indexed citations

20.

Simon, Jeremy M., Kathryn E. Hacker, Darshan Singh, et al.. (2013). Variation in chromatin accessibility in human kidney cancer links H3K36 methyltransferase loss with widespread RNA processing defects. Genome Research. 24(2). 241–250. 137 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact